Role of Famotidine in the Clinical Improvement of COVID-19 Patients.

Chattogram General Hospital

Status and phase

Completed

Phase 3

Conditions

Covid19

Treatments

Drug: Famotidine 20 MG

Study type

Interventional

Funder types

Other

Identifiers

NCT04504240

10000753/980

Details and patient eligibility

About

This study is aimed to investigate the effect of Famotidine in the clinical recovery of COVID-19 patients. COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Like other countries of the world, Besides antiviral drugs, immunosuppressive agents, and symptomatic therapy like H2 receptor blocker FAMOTIDINE came to the limelight due to its role in reducing the symptoms of COVID-19 patients. The study will include COVID-19 participants to confirm by RT PCR or an HRCT chest. Detail history of each participant with comorbidity will be taken and will be examined carefully. The hospitalized patients admitted to the HDU/ICU units will be enrolled in this study. Critically ill patients who require ventilator support will not be included in this study. The outcome of the Famotidine treatment will be evaluated and compared with a control group.

Enrollment

208 patients

Sex

All

Ages

16 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

SARS-CoV-2 infection confirmed by RT PCR or CT Chest.
Severe COVID-19 patients require hospitalization under HDU/ICU.

Exclusion criteria

Patients with severe and/or uncontrolled medical conditions with significantly compromised organ function.
Patients who were hospitalized from the before due to other reasons.
Contraindication / possible drug interaction with Famotidine with existing therapy.
Immunocompromised patients.
Pregnancy, Pulmonary Tuberculosis, AIDS